Hemorrhage Control and Massive Transfusion

Haemorrhage control and massive transfusion concern the recognition and treatment of major bleeding after injury — the leading cause of potentially preventable trauma death. Management combines physical control of bleeding sources with damage-control resuscitation: balanced transfusion of blood products, limitation of crystalloid, and measures to counter the self-reinforcing cycle of coagulopathy, acidosis, and hypothermia.

Definition

Haemorrhage control is the identification and arrest of bleeding after injury, and massive transfusion is the structured replacement of large volumes of blood and blood components, undertaken within a damage-control resuscitation strategy aimed at restoring perfusion while limiting coagulopathy.

Scope

This entry covers the concept of haemorrhagic shock, the trauma-induced coagulopathy that complicates it, balanced ('damage-control') resuscitation, massive transfusion strategies, and the role of antifibrinolytic therapy as established by major trials. It is a reference and educational overview of how major-bleeding management is organised, not a dosing guide or a source of individualised treatment instructions.

Core questions

• Is the patient in haemorrhagic shock and what is the source of bleeding?
• How is bleeding physically controlled and when is surgical or interventional control needed?
• How should blood products be given to avoid worsening coagulopathy?
• What role do antifibrinolytics such as tranexamic acid play, and within what time window?

Key concepts

• Haemorrhagic shock
• Trauma-induced coagulopathy
• Lethal triad (coagulopathy, acidosis, hypothermia)
• Damage-control resuscitation
• Balanced (1:1:1) transfusion
• Massive transfusion protocol
• Permissive hypotension
• Antifibrinolytic therapy (tranexamic acid)

Mechanisms

Severe blood loss reduces oxygen delivery and produces haemorrhagic shock; if uncorrected it triggers tissue hypoperfusion, lactic acidosis, hypothermia, and a coagulopathy that together accelerate bleeding — the so-called lethal triad. Damage-control resuscitation responds by prioritising rapid haemorrhage control, restricting clear fluids, and transfusing red cells, plasma, and platelets in balanced ratios to reconstitute something closer to whole blood. The PROPPR trial examined balanced 1:1:1 versus 1:1:2 transfusion, and the CRASH-2 trial established that the antifibrinolytic tranexamic acid, given early after injury, reduces death from bleeding. European and North American practice guidelines synthesise these strategies into structured approaches to the bleeding trauma patient.

Clinical relevance

Major haemorrhage is the most common cause of preventable death in the first hours after injury, and emergency and critical-care nurses are central to activating massive transfusion protocols, administering balanced products, and monitoring the response. Understanding these concepts helps the team coordinate rapid resuscitation; the content here is educational and does not provide dosing, individualised treatment, or a substitute for institutional protocols.

Epidemiology

Uncontrolled haemorrhage accounts for a large share of early trauma deaths and the majority of those judged potentially preventable, particularly in penetrating injury and high-energy blunt trauma. Battlefield and civilian data alike identify bleeding as a dominant, time-sensitive cause of mortality, motivating systems to deliver blood products and antifibrinolytics early.

History

Damage-control resuscitation emerged from military and civilian trauma experience in the late twentieth and early twenty-first centuries, shifting practice away from large-volume crystalloid toward early balanced transfusion. The CRASH-2 trial (2010) brought antifibrinolytic therapy into evidence-based trauma resuscitation, and the PROPPR trial (2015) tested transfusion ratios directly; successive European trauma bleeding guidelines have consolidated the field.

Debates

What is the optimal ratio of blood products in massive transfusion?

Balanced transfusion approximating whole blood is widely advocated, but the precise ratio — for example 1:1:1 versus 1:1:2 — and how strictly to adhere to it remain matters of ongoing study, as reflected in the PROPPR trial and subsequent guidelines.

Seminal works

• crash2-2010
• holcomb-2015
• spahn-2019

Frequently asked questions

What is damage-control resuscitation?

It is a resuscitation strategy for major bleeding that prioritises rapid haemorrhage control, limits clear-fluid administration, and replaces blood loss with balanced ratios of red cells, plasma, and platelets to limit coagulopathy.

Why is tranexamic acid associated with trauma haemorrhage?

The CRASH-2 trial showed that tranexamic acid, an antifibrinolytic given early after injury, reduced death due to bleeding in trauma patients with significant haemorrhage, which is why it features in trauma resuscitation guidelines.